Acrospire Investment Management LLC Holds Position in Celgene Corporation (CELG)

Acrospire Investment Management LLC held its stake in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 901 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Acrospire Investment Management LLC’s holdings in Celgene Corporation were worth $117,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in CELG. Thompson Davis & CO. Inc. increased its holdings in Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the last quarter. Motco increased its holdings in Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 159 shares during the last quarter. Penserra Capital Management LLC purchased a new stake in Celgene Corporation during the second quarter valued at approximately $129,000. Acropolis Investment Management LLC purchased a new stake in Celgene Corporation during the second quarter valued at approximately $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 380 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on CELG shares. Morgan Stanley cut shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research note on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Celgene Corporation in a research note on Sunday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and issued a $112.00 price objective on shares of Celgene Corporation in a research note on Monday, October 30th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective for the company in a research note on Monday, October 23rd. Finally, Citigroup Inc. cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene Corporation presently has a consensus rating of “Buy” and an average target price of $139.57.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the transaction, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock valued at $2,843,956 in the last quarter. 0.95% of the stock is owned by company insiders.

Celgene Corporation (NASDAQ:CELG) opened at $105.16 on Thursday. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market cap of $82,274.63, a price-to-earnings ratio of 16.33, a P/E/G ratio of 0.81 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the business earned $1.58 earnings per share. Celgene Corporation’s quarterly revenue was up 10.2% compared to the same quarter last year. analysts expect that Celgene Corporation will post 6.67 EPS for the current year.

WARNING: This story was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://transcriptdaily.com/2017/11/23/acrospire-investment-management-llc-holds-position-in-celgene-corporation-celg.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply